You're Taking Statins as Prescribed and Still Have Muscle Pain. Here's Why.

CYP2D6 is one of your liver’s most important drug-processing enzymes. It metabolizes roughly 25% of all medications, including certain statins, antidepressants, and pain relievers. Its job is to transform lipophilic (fat-soluble) drugs into water-soluble metabolites that your body can eliminate.

Here’s the problem: the CYP2D6 gene comes in multiple variants (including *2, *4, *10, and *17), and some of these variants severely reduce enzyme activity. Poor metabolizers, who carry two loss-of-function variants, represent roughly 7 to 10% of people with European ancestry. In these individuals, statin clearance slows dramatically, and the drug accumulates in blood and muscle tissue to potentially toxic levels.

If you’re a poor CYP2D6 metabolizer taking a standard statin dose, you’re essentially taking two or three times the intended dose. Your muscle cells are exposed to sustained high concentrations of the drug. Muscle pain, weakness, and breakdown become inevitable consequences, not rare side effects.

CYP2C19 metabolizes a range of drugs including certain statins, proton pump inhibitors, and some antidepressants. It’s a backup enzyme for statin clearance, meaning some statins rely on it as a secondary pathway after CYP2D6 or CYP3A4 finishes the primary breakdown.

The CYP2C19 gene carries variants (*2 and *3) that severely impair its function. Poor metabolizers for CYP2C19 represent roughly 2 to 15% of the population depending on ancestry. If you’re a poor metabolizer for both CYP2D6 and CYP2C19, statin clearance becomes extremely slow, and myopathy risk rises substantially.

You may not have obvious symptoms at first. But as the statin accumulates week after week, muscle soreness begins during exercise. Then it persists at rest. Then it worsens. Your doctor may suspect myositis or fibromyalgia when the real cause is drug accumulation from slow CYP2C19 metabolism.

SLCO1B1 encodes a transport protein that pumps statins from your bloodstream into liver cells, where they do their job of lowering cholesterol. Without efficient SLCO1B1 function, statins remain in your systemic circulation instead of concentrating where they belong, and they can’t reach enough liver cells to lower cholesterol effectively.

The most common functionally relevant variant is *5 (rs4149056), which carries a C allele present in roughly 15% of the European ancestry population. People with the CC or CT genotype have significantly reduced statin uptake into the liver, meaning more statin stays in the bloodstream, muscles, and other tissues, dramatically elevating myopathy risk.

This is why simvastatin, a lipophilic statin that depends heavily on SLCO1B1 for hepatic uptake, causes muscle pain more often in people with SLCO1B1 variants. You’re not metabolizing the statin slowly. You’re just not moving it into the liver efficiently, so it lingers in muscle and nerve tissue where it damages cells.

CYP2C9 is responsible for metabolizing warfarin (a blood thinner), many NSAIDs, and certain statins. It’s a workhorse enzyme that handles a wide range of lipophilic drugs. Like CYP2D6, it comes in multiple variants (*2 and *3) that reduce enzyme activity.

Poor metabolizers for CYP2C9 represent roughly 5 to 10% of people with European ancestry. In poor metabolizers, statin clearance slows, and systemic exposure increases, raising the risk of muscle breakdown and myopathy at standard doses.

The challenge is that CYP2C9 poor metabolizers also have trouble with many other drugs, making medication management complex. If you’re a poor metabolizer for both CYP2C9 and SLCO1B1, statin accumulation becomes severe, and even low doses may cause muscle pain. Your doctor may not realize that two genetic factors are compounding each other.

VKORC1 encodes vitamin K epoxide reductase, an enzyme that recycles vitamin K, which is essential for blood clotting factor synthesis. While VKORC1 isn’t directly involved in statin metabolism, it’s relevant because people taking statins are often also on anticoagulants like warfarin, and VKORC1 variants profoundly affect warfarin dosing.

The -1639G>A variant in VKORC1 is common, with the A allele present in roughly 40% of people with European ancestry. People with the A allele have reduced vitamin K recycling, meaning they’re extremely sensitive to warfarin and require much lower doses to achieve therapeutic anticoagulation.

This matters for statin muscle pain because if you’re on both a statin and warfarin, and you carry VKORC1 A alleles, you’re likely on a lower warfarin dose. Some drug interactions between statins and warfarin are mediated through CYP metabolism. If your warfarin dose is already adjusted downward for VKORC1 variants, adding a statin may cause unexpected drug interaction effects, including increased bleeding risk or reduced anticoagulation, which can complicate your medication regimen and lead to doctors incorrectly attributing muscle symptoms to the statin alone.

TPMT metabolizes thiopurine drugs like azathioprine and 6-mercaptopurine, which are used to treat autoimmune conditions and certain cancers. While TPMT isn’t directly involved in statin metabolism, it’s relevant because people on immunosuppressive therapy sometimes also take statins (for cardiovascular protection in autoimmune disease).

There are multiple TPMT variants, and poor metabolizers represent roughly 0.3% of the population. TPMT poor metabolizers accumulate toxic thiopurine metabolites, causing severe bone marrow suppression, but they can metabolize statins normally.

However, if you’re a TPMT poor metabolizer on thiopurines (even at reduced doses) and you add a statin, you now have two drugs to manage at reduced levels. The combination can increase overall drug-induced toxicity and inflammation, potentially worsening muscle symptoms through immune-mediated mechanisms. Additionally, bone marrow suppression from thiopurines can impair muscle recovery and repair, making statin-induced myopathy symptoms feel worse.